Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer.
Saved in:
| Title: | Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer. |
|---|---|
| Authors: | Edwards DN; Division of Rheumatology and Immunology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Ngwa VM; Program in Cancer Biology, Vanderbilt University, Nashville, Tennessee, USA., Raybuck AL; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Wang S; Division of Rheumatology and Immunology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Hwang Y; Division of Rheumatology and Immunology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Kim LC; Program in Cancer Biology, Vanderbilt University, Nashville, Tennessee, USA., Cho SH; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Paik Y; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Wang Q; Department of Biological Sciences, College of Science, University of Notre Dame, Notre Dame, Indiana, USA.; Mike and Josie Harper Cancer Research Institute, University of Notre Dame, South Bend, Indiana, USA., Zhang S; Department of Biological Sciences, College of Science, University of Notre Dame, Notre Dame, Indiana, USA.; Mike and Josie Harper Cancer Research Institute, University of Notre Dame, South Bend, Indiana, USA., Manning HC; Department of Chemistry.; Center for Molecular Probes.; Vanderbilt Institute for Imaging Sciences.; Department of Radiology and Radiological Sciences.; Vanderbilt-Ingram Cancer Center., Rathmell JC; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Vanderbilt-Ingram Cancer Center.; Vanderbilt Institute for Infection, Immunology and Inflammation, and., Cook RS; Program in Cancer Biology, Vanderbilt University, Nashville, Tennessee, USA.; Vanderbilt-Ingram Cancer Center.; Department of Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Boothby MR; Division of Rheumatology and Immunology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Program in Cancer Biology, Vanderbilt University, Nashville, Tennessee, USA.; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Vanderbilt Institute for Infection, Immunology and Inflammation, and., Chen J; Division of Rheumatology and Immunology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Program in Cancer Biology, Vanderbilt University, Nashville, Tennessee, USA.; Vanderbilt-Ingram Cancer Center.; Vanderbilt Institute for Infection, Immunology and Inflammation, and.; Department of Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Veterans Affairs Medical Center, Tennessee Valley Healthcare System, Nashville, Tennessee, USA. |
| Source: | The Journal of clinical investigation [J Clin Invest] 2021 Feb 15; Vol. 131 (4). |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. |
| Journal Info: | Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
